An overview of precision oncology basket and umbrella trials for clinicians

Abstract

With advancements in biomarkers and momentum in precision medicine, biomarker‐guided trials such as basket trials and umbrella trials have been developed under the master protocol framework. A master protocol refers to a single, overarching design developed to evaluate multiple hypotheses with the general goal of improving the efficiency of trial evaluation. One type of master protocol is the basket trial, in which a targeted therapy is evaluated for multiple diseases that share common molecular alterations or risk factors that may help predict whether the patients will respond to the given therapy. Another variant of a master protocol is the umbrella trial, in which multiple targeted therapies are evaluated for a single disease that is stratified into multiple subgroups based on different molecular or other predictive risk factors. Both designs follow the core principle of precision medicine—to tailor intervention strategies based on the patient's risk factor(s) that can help predict whether they will respond to a specific treatment. There have been increasing numbers of basket and umbrella trials, but they are still poorly understood. This article reviews common characteristics of basket and umbrella trials, key trials and recent US Food and Drug Administration approvals for precision oncology, and important considerations for clinical readers when critically evaluating future publications on basket trials and umbrella trials and for researchers when designing these clinical trials.

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

“…Up to 50% of CCAs have current druggable mutations, amplifications or fusions (for example, IDH1, IDH2, BRAF, FGFR, HER2, PIK3CA, MET, among others), opening a new opportunity for therapeutic intervention that deserves intense basic and clinical research. In fact, targeting these mutations is amenable and is already a reality in other types of cancer 389,390 . In this scenario, the treatment of patients with breast cancer or colorectal cancer with trastuzumab (anti-HER2) 391 and cetuximab-panitumumab (anti-EGFR) 392 is an example of the successful use of targeted therapy.…”

Emerging role of long noncoding RNA-encoded micropeptides in cancer

“…New cancer treatments, such as immunotherapy and targeted therapy, have emerged in recent years, and their combinations with traditional surgery, radiotherapy, and chemotherapy have greatly improved the prognosis of some cancer patients; however, the overall survival rate for most patients remains poor [69,70]. The health hazards and huge social burden associated with cancer have stimulated extensive research.…”

Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to

“…Asynchronous introduction of combination drugs should be considered when in the designing of trials. For example, it will be better to learn about the difference of the effect, safety and tolerance of monotherapy and combinationdrug when adding a monotherapy phase before combination-drug phase [98,99].…”